Use of a csrnpi inhibitor in the preparation of a medicament for the treatment of liver ischemia reperfusion injury
By designing CSRNP1 inhibitors to interfere with CSRNP1 gene expression and inhibit the MAPK pathway, the problem of effective treatment for hepatic ischemia-reperfusion injury was solved, significantly reducing hepatocyte apoptosis and providing a new molecular mechanism for the treatment of HIRI.
Patent Information
- Application Number
- CN202311350004.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-18
- Publication Date
- 2026-06-26
- Estimated Expiration
- 2043-10-18
AI Technical Summary
Current technologies lack effective drugs to prevent or treat liver ischemia-reperfusion injury (HIRI), especially given the high incidence of early graft dysfunction (EAD) after liver transplantation and the worsening situation when using extended standard donors (ECD). The role of altered CSRNP1 gene expression in HIRI remains unclear.
We designed siRNA and shRNA targeting the CSRNP1 gene as CSRNP1 inhibitors. By inhibiting the expression or activity of the CSRNP1 gene, we interfered with the MAPK pathway, especially the phosphorylation of SAPK, and reduced hepatocyte apoptosis.
It significantly reduces hepatocyte apoptosis after hypoxia-reoxygenation, alleviates HIRI, provides a new molecular mechanism for the treatment of HIRI, and offers a new strategy for clinical treatment.
